AngioDynamics, Inc.(ANGO)

$15.49—Stale · unknown oldEarnings in 5d

WatchlistAsk SA Chart

AngioDynamics, Inc.(ANGO)

NASDAQ • Last print unknown ago

$15.49—Stale · unknown oldEarnings in 5d

WatchlistAsk SA Chart Studio

ANGO(ANGO)

ANGO

9/26/26

AngioDynamics (ANGO)

Saturday

3:51 PM

ThesisAngioDynamics: the story is balanced — Vascular Access product line stabilization - reversing recent revenue declines in core catheter business

Revenue Outlook

Metric	FY2026	FY2027E	FY2028E
Revenue	$320M	$337M	$355M
Rev. Growth	+9.5%	+5.4%	+5.3%
EPS	$-0.88	$-0.27	$-0.04
EPS Growth	-6.0%	+69.8%	+83.1%
P/E	—	—	—

★ Analysts see FY2027 revenue reaching $337M — +5.4% growth in a single year.

What Moves the Stock

01Vascular Access product line stabilization - reversing recent revenue declines in core catheter business
02NanoKnife ablation system adoption rates and clinical trial outcomes for expanded indications
03Hospital procedure volumes and capital equipment spending trends post-COVID normalization
04Gross margin trajectory - ability to maintain 53-54% despite pricing pressure and product mix shifts
05Path to profitability milestones - operating expense management and breakeven timeline
06Vascular Access products (dialysis catheters, PICC lines, ports) - estimated 40-45% of revenue
07Peripheral Vascular Interventions (thrombectomy, angioplasty, venous disease treatments) - estimated 30-35% of revenue
08Oncology/Surgery products (NanoKnife ablation system, microwave ablation) - estimated 20-25% of revenue

FY2026 Snapshot

Revenue: $320M
Rev. Growth: +9.5%
Gross Margin: 54.6%
Op. Margin: -12.5%
Net Margin: -11.5%
Net Income: $-37M
NI Growth: -8.1%
EPS: $-0.88
1Y Return: +44.5%

My Notes

value/turnaround - The stock attracts contrarian investors betting on operational turnaround, cost restructuring, or acquisition potential.
Rising interest rates have moderate negative impact through two channels: (1) higher discount rates compress valuation multiples…
Watch on earnings: Monthly hospital procedure volumes and surgical case counts - leading indicator of device demand, Medicare reimbursement rate changes for vascular access and interventional procedures, FDA approval timelines and clinical trial enrollment for NanoKnife expanded indications.

One Sentence Summary:

AngioDynamics: the story is balanced — vascular access product line stabilization - reversing recent revenue declines in core catheter business.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Metric

FY2026

FY2027E

FY2028E

P/E

—

What Moves the Stock

01Vascular Access product line stabilization - reversing recent revenue declines in core catheter business

02NanoKnife ablation system adoption rates and clinical trial outcomes for expanded indications

03Hospital procedure volumes and capital equipment spending trends post-COVID normalization

04Gross margin trajectory - ability to maintain 53-54% despite pricing pressure and product mix shifts

05Path to profitability milestones - operating expense management and breakeven timeline

06Vascular Access products (dialysis catheters, PICC lines, ports) - estimated 40-45% of revenue

07Peripheral Vascular Interventions (thrombectomy, angioplasty, venous disease treatments) - estimated 30-35% of revenue

08Oncology/Surgery products (NanoKnife ablation system, microwave ablation) - estimated 20-25% of revenue

My Notes

value/turnaround - The stock attracts contrarian investors betting on operational turnaround, cost restructuring, or acquisition potential.

Rising interest rates have moderate negative impact through two channels: (1) higher discount rates compress valuation multiples…

Watch on earnings: Monthly hospital procedure volumes and surgical case counts - leading indicator of device demand, Medicare reimbursement rate changes for vascular access and interventional procedures, FDA approval timelines and clinical trial enrollment for NanoKnife expanded indications.

AngioDynamics (ANGO)

Revenue Outlook

What Moves the Stock

ANGO Chart

My Notes

One Sentence Summary:

Explore More

AngioDynamics (ANGO)

Revenue Outlook

What Moves the Stock

ANGO Chart

My Notes

One Sentence Summary: